0018). Multivariate regression analysis demonstrated that age younger than 48 years was an independent risk factor for recurrent PBC in recipients undergoing liver transplantation (hazard ratio 0.028, 95% confidence interval 0.01-0.71, =0.03). Posttransplant infections (62%) and biliary tract complications (26%) were the most common complications. Liver transplantation is an effective treatment for patients with PBC. Liver function normalizes by 4 weeks posttransplant. Although posttransplant survival rate is high, recurrence is possible. To some extent, survival rate and recurrence rate can be predicted by APRI and age, respectively. Liver transplantation is an effective treatment for patients with PBC. Liver function normalizes by 4 weeks posttransplant. Although posttransplant survival rate is high, recurrence is possible. To some extent, survival rate and recurrence rate can be predicted by APRI and age, respectively.[This corrects the article DOI 10.1167/tvst.8.6.9.]. Assess feasibility and interexaminer reliability of a new test of contrast sensitivity (CS) for pediatric populations. The Double Happy (DH) measures CS using a method similar to the Teller Acuity Cards. The schematic DH face is 16 degrees in diameter with features of 0.3 c/d and a channel frequency of 0.8 c/d. DH log CS is in 0.15 log unit steps, 0.05 to 2.1. Participants were 43 unselected patients, ages 2 to 18 years 23 were diagnosed with ocular disorders only; 20 were diagnosed with cerebral visual impairment (CVI). Two examiners measured DH log CS. Visual acuity (VA) was also measured. All 43 participants were tested for binocular DH log CS. Cohen's kappa values for interexaminer reliability were fair. The between examiner ICC was +0.92 ( < 0.001). The mean difference between examiners was near zero, and the 95% CI was -0.44 to 0.45 log CS. DH log CS was near normal in the ocular disorder group and reduced in the CVI group. VA was reduced in both groups. DH log CS and VA were correlated ( = -0.65). DH log CS was a marginally better predictor of diagnosis than VA. DH log CS test was successful in a diverse pediatric population diagnosed with ocular disorders or CVI. Interexaminer reliability was comparable to that of adults tested previously using the same stimuli and methods. Both CS and VA are reduced in CVI. CS and VA both should be tested in pediatric clinical populations, especially in those at risk of CVI. CS and VA both should be tested in pediatric clinical populations, especially in those at risk of CVI. To test the validity of the ASTEROID stereotest as a clinical test of depth perception by comparing it to clinical and research standard tests. Thirty-nine subjects completed four stereotests twice the ASTEROID test on an autostereo 3D tablet, a research standard on a VPixx PROPixx 3D projector, Randot Circles, and Randot Preschool. Within 14 days, subjects completed each test for a third time. ASTEROID stereo thresholds correlated well with research standard thresholds ( = 0.87, < 0.001), although ASTEROID underestimated standard threshold (mean difference = 11 arcsec). ASTEROID results correlated less strongly with Randot Circles ( = 0.54, < 0.001) and Randot Preschool ( = 0.64, < 0.001), due to the greater measurement range of ASTEROID (1-1000 arcsec) compared to Randot Circles or Randot Preschool. Stereo threshold variability was low for all three clinical stereotests (Bland-Altman 95% limits of agreement between test and retest ASTEROID, ±0.37; Randot Circles, ±0.24; Randot Preschool, ±0.23). ASTEROID captured the largest range of stereo in a normal population with test-retest reliability comparable to research standards (immediate = 0.86 for ASTEROID vs. 0.90 for PROPixx; follow-up = 0.68 for ASTEROID vs. 0.88 for PROPixx). Compared to clinical and research standards for assessing depth perception, ASTEROID is highly accurate, has good test-retest reliability, and measures a wider range of stereo threshold. The ASTEROID stereotest is a better clinical tool for determining baseline stereopsis and tracking changes during treatment for amblyopia and strabismus compared to current clinical tests. The ASTEROID stereotest is a better clinical tool for determining baseline stereopsis and tracking changes during treatment for amblyopia and strabismus compared to current clinical tests. To validate the application of a known transgenic mouse line with green fluorescent cones (Chrnb4.EGFP) to study cone photoreceptor biology and function in health and disease. Chrnb4.EGFP retinas containing GFP cones were compared with retinas without the GFP transgene via immunohistochemistry, quantitative real-time polymerase chain reaction, electroretinograms, and flow cytometry. The Chrnb4.EGFP line was backcrossed to the mouse models of cone degeneration, and , generating the new lines .GFP and .GFP, which were also studied as described. GFP expression spanned the length of the cone cell in the Chrnb4.EGFP line, as well as in the novel .GFP and .GFP lines. The effect of GFP expression showed no significant changes to outer nuclear layer cell death, cone-specific gene expression, and immune response activation. A temporal decrease in GFP expression over time was observed, but GFP fluorescence was still detected through flow cytometry as late as 6 months. https://www.selleckchem.com/products/sb-505124.html Furthermore, a functional analysis of photopic and scotopic electroretinogram responses of the Chrnb4 mouse showed no significant difference between GFP and GFP mice, whereas electroretinogram recordings for the .GFP and .GFP lines matched previous reports from the original lines. This study demonstrates that the Chrnb4.EGFP mouse can be a powerful tool to overcome the limitations of studying cone biology, including the use of this line to study different types of cone degeneration. This work validates research tools that could potentially offer more reliable preclinical data in the development of treatments for cone-mediated vision loss conditions, shortening the gap to clinical translation. This work validates research tools that could potentially offer more reliable preclinical data in the development of treatments for cone-mediated vision loss conditions, shortening the gap to clinical translation.